ad image

Rare Disease

1 / 1
From Patients to Partners: The Rising Power of Advocacy in Drug Development
Advocacy

From Patients to Partners: The Rising Power of Advocacy in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

PAO-25-30-19Mar 13, 2025
From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs
Orphan Drugs

From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-25-30-06Mar 02, 2025
Passion and Understanding Essential for Rare Disease Clinical Trials
Clinical Trials

Passion and Understanding Essential for Rare Disease Clinical Trials

Juliet Moritz

Ergomed

PAO-10-24-CL-03Oct 29, 2024
Optimizing Oncology and Rare Disease Clinical Trials by Focusing on Science and Aligning with both Patients and Investigators
Clinical Trials

Optimizing Oncology and Rare Disease Clinical Trials by Focusing on Science and Aligning with both Patients and Investigators

Dave Selkirk

Ergomed

PAO-06-24-CL-09May 30, 2024
Staying Agile to Bring Therapies to Patients with Rare Diseases
Rare Diseases

Staying Agile to Bring Therapies to Patients with Rare Diseases

Sheila Frame

Amryt Pharma

PAO-06-022-CL-08Jun 21, 2022
Rare Disease Patients Benefit from Clinical Trial Flexibility
Rare Disease Clinical Trials

Rare Disease Patients Benefit from Clinical Trial Flexibility

Tim Rich; Meredith McCumbee; Francis Jones, Ph.D.

PPD, part of Thermo Fisher Scientific

PAO-02-022-CL-03Mar 12, 2022
Leveraging AI and RNA to Fight Rare Diseases
Rare Diseases

Leveraging AI and RNA to Fight Rare Diseases

Envisagenics

PAO-02-22-R250-17Feb 24, 2022
Beyond 2020: Looking into the Crystal Ball for Gene Therapy
Gene Therapy

Beyond 2020: Looking into the Crystal Ball for Gene Therapy

Ratish Krishnan

MilliporeSigma

PAO-01-21-CL-03Feb 01, 2021
Developing Transformative Treatments for Rare Endocrine Diseases
Endocrine Diseases

Developing Transformative Treatments for Rare Endocrine Diseases

Abraham N. Ceesay

Tiburio Therapeutics

PAP-Q2-20-CL-023Jul 01, 2020
Pfizer
Drug Approval

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

Pfizer

PR-M05-19-NI-036May 13, 2019
Facilitating Complex Clinical Trials For Rare Diseases
Clinical Trial Logistics

Facilitating Complex Clinical Trials For Rare Diseases

Ariette van Strien

Marken

PAP-Q1-2019-CL-003Mar 12, 2019
REGENXBIO
Cell and Gene Therapy

REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

REGENXBIO

PR-M11-18-NI-028Nov 08, 2018
Patients with Rare Leukemia Disease Will Have New Treatment Option
Drug Development

Patients with Rare Leukemia Disease Will Have New Treatment Option

Nigel Walker

Nice Insight

PAO-M09-18-NI-016Sep 21, 2018
Expansion Therapeutics, Inc.
Business

Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases

Expansion Therapeutics, Inc.

PR-M01-18-NI-009Jan 03, 2018
1 / 1